Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 2/20 | 0.40 |
| ▸ | EDNRA | P25101 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149620 | 0.75 | CHRNB2 (0.40) | CES2HPGDPARP1KDM1AKDM1B | |
| SCHEMBL1149629 | 0.75 | CHRNB2 (0.40) | CES2HPGDPARP1ALDH1A1KMT2A | |
| SCHEMBL6862889 | 0.75 | HDAC3 (0.51) | ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL14916078 | 0.72 | HDAC4 (0.41) | EDNRBEDNRACES2ALOX15ALDH1A1 | |
| SCHEMBL14124713 | 0.71 | EDNRB (0.47) | EDNRBEDNRACYP1A2CES2GALR3 | |
| SCHEMBL8209416 | 0.67 | AHR (0.47) | EDNRBEDNRACYP1A2CYP2C19MAPK1 | |
| SCHEMBL14124766 | 0.64 | EDNRB (0.50) | EDNRBEDNRACYP1A2MAPK1ALDH1A1 | |
| SCHEMBL29536401 | 0.64 | KDM1A (0.43) | CYP1A2ALOX15KDM1AKDM1BKDM4E | |
| SCHEMBL22203925 | 0.63 | MEN1 (0.38) | EDNRBEDNRACYP1A2CYP2C9ALOX15 | |
| SCHEMBL998511 | 0.63 | EDNRB (0.44) | EDNRBEDNRACYP1A2CES2GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7615572-B2 | 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia | SEPRACOR INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488747-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1709004-A2 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | Sepracor Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005066135-A2 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | DDO, DAO, SRR | EDNRB 3510/4885EDNRA 2717/4885CYP1A2 3265/4885 |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | EDNRB 3510/4885EDNRA 2717/4885CYP1A2 3265/4885 |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | DDO, DAO, SRR | EDNRB 3510/4885EDNRA 2717/4885CYP1A2 3265/4885 |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | EDNRB 3510/4885EDNRA 2717/4885CYP1A2 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.